Gray matter density reduction associated with adjuvant chemotherapy in older women with breast cancer

Bihong T. Chen, Taihao Jin, Sunita K. Patel, Ningrong Ye, Can Lan Sun, Huiyan Ma, Russell C. Rockne, James C. Root, Andrew J. Saykin, Tim A. Ahles, Andrei I. Holodny, Neal Prakash, Joanne Mortimer, James Waisman, Yuan Yuan, Daneng Li, George Somlo, Jessica Vazquez, Abrahm Levi, Heidi TanRichard Yang, Vani Katheria, Arti Hurria

Research output: Contribution to journalArticle

5 Scopus citations

Abstract

Purpose: The purpose of this study was to evaluate longitudinal changes in brain gray matter density (GMD) before and after adjuvant chemotherapy in older women with breast cancer. Methods: We recruited 16 women aged ≥ 60 years with stage I–III breast cancers receiving adjuvant chemotherapy (CT) and 15 age- and sex-matched healthy controls (HC). The CT group underwent brain MRI and the NIH Toolbox for Cognition testing prior to adjuvant chemotherapy (time point 1, TP1) and within 1 month after chemotherapy (time point 2, TP2). The HC group underwent the same assessments at matched intervals. GMD was evaluated with the voxel-based morphometry. Results: The mean age was 67 years in the CT group and 68.5 years in the HC group. There was significant GMD reduction within the chemotherapy group from TP1 to TP2. Compared to the HC group, the CT group displayed statistically significantly greater GMD reductions from TP1 to TP2 in the brain regions involving the left anterior cingulate gyrus, right insula, and left middle temporal gyrus (pFWE(family-wise error)-corrected < 0.05). The baseline GMD in left insula was positively correlated with the baseline list-sorting working memory score in the HC group (pFWE-corrected < 0.05). No correlation was observed for the changes in GMD with the changes in cognitive testing scores from TP1 to TP2 (pFWE-corrected < 0.05). Conclusions: Our findings indicate that GMD reductions were associated with adjuvant chemotherapy in older women with breast cancer. Future studies are needed to understand the clinical significance of the neuroimaging findings. This study is registered on ClinicalTrials.gov (NCT01992432).

Original languageEnglish (US)
Pages (from-to)363-370
Number of pages8
JournalBreast Cancer Research and Treatment
Volume172
Issue number2
DOIs
StatePublished - Nov 1 2018

Keywords

  • Breast cancer
  • Chemotherapy
  • Cognition
  • Gray matter density (GMD)
  • Voxel-based morphometry (VBM)

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Gray matter density reduction associated with adjuvant chemotherapy in older women with breast cancer'. Together they form a unique fingerprint.

  • Cite this

    Chen, B. T., Jin, T., Patel, S. K., Ye, N., Sun, C. L., Ma, H., Rockne, R. C., Root, J. C., Saykin, A. J., Ahles, T. A., Holodny, A. I., Prakash, N., Mortimer, J., Waisman, J., Yuan, Y., Li, D., Somlo, G., Vazquez, J., Levi, A., ... Hurria, A. (2018). Gray matter density reduction associated with adjuvant chemotherapy in older women with breast cancer. Breast Cancer Research and Treatment, 172(2), 363-370. https://doi.org/10.1007/s10549-018-4911-y